Conference Coverage

In era of infliximab, ulcerative colitis surgical outcomes worsen


 

AT THE ACS CLINICAL CONGRESS

– The era of powerful biologics has led to unforeseen surgical outcomes in patients with ulcerative colitis.

Patients undergoing surgery for ulcerative colitis now are 38% more likely to die in the hospital than they were 15 years ago, before infliximab and other biologics were adopted as medical therapy for the disease. A database review covering 18 years found that other surgical outcomes are worse, too, Jonathan Abelson, MD, said at the annual clinical congress of the American College of Surgeons.

Dr. Jonathan Abelson

The drugs themselves are not creating the poor outcomes per se, Dr. Abelson said in an interview. Rather, biologics are controlling inflammatory bowel disease well in patients with mild-moderate disease, and leaving the sickest patients in the surgical pool.

“These very powerful agents could be completely eliminating the need for surgery in patients with mild disease, leaving surgery for those who have very advanced disease and didn’t respond well to medical therapy,” said Dr. Abelson, a clinical research fellow at New York–Presbyterian Hospital, N.Y. “We are operating now only on patients with very severe disease, not the wider range of patients we had 15 years ago, when there weren’t as effective medical options.”

He and his colleagues used the New York Statewide Planning and Research Cooperative System (SPARCS) database to identify 7,070 patients who had undergone bowel resection for ulcerative colitis during two epochs: prebiologics (1995-2005) and postbiologics (2006-2013). The cohorts were about evenly split in numbers.

There were some statistically significant differences in baseline characteristics. Patients in epoch 2 were about a year older (51 vs. 50 years). Significantly more of them had at least two major comorbidities (28% vs. 18%). Minimally invasive surgery was significantly more common in epoch 2 (28% vs. 3%).

Significantly more surgeries in epoch 2 were staged into three or more procedures (14% vs. 9%). This finding probably reflects the level of disease severity in those presenting for surgery or the fact that they underwent surgery after recently receiving biologics, Dr. Abelson said.

“One of the limits of this study is that we don’t know exactly the reasons for these one-, two-, or three-stage surgeries. The theory is that patients who were more ill at presentation are more likely to have a multistaged surgery. Another reason could be that if they are on these powerful immunosuppressive regimens, the surgeon might be concerned about not healing well from a definitive one- or two-stage surgery.”

He then conducted a multivariate analysis that controlled for baseline factors, including a variety of individual comorbid conditions. In this analysis, patients in epoch 2 were 38% more likely to die in the hospital and 51% more likely to experience a major postoperative event, like shock, pulmonary embolism, stroke, or heart attack. The chance of a surgical complication was increased by 39%, and these patients were 25% more likely to need a transfusion during surgery than those from epoch 1.

The poorer outcomes held for an at least an entire year after surgery, Dr. Abelson said. At 1 year, patients in epoch 2 were 36% more likely to have a readmission than those in epoch 1. Major events and procedural complications were both 46% more likely. Patients were also 36% more likely to require an additional procedure.

“These are not the outcomes we want to see, especially in this era when our surgical techniques have improved so much,” Dr. Abelson said. “If what this represents, though, is that we are now operating on a higher-risk population, we can’t just say, ‘Well, that’s how it’s going to be.’ We need to figure out how to minimize morbidity and mortality in this high-risk patient population.”

One goal, he suggested, would be to assess response to a biologic regimen earlier in the hopes of determining who will respond well, and moving ahead with surgery in those who don’t.

This is a tough sell for patients, he said.

“There is a big fear of this surgery. It usually requires a temporary ileostomy and a stoma bag, and patients are terrified of that. There have been a few studies demonstrating that earlier referral to surgery improves quality of life; living with advanced ulcerative colitis can be extremely difficult and patients often feel a lot better after we remove their diseased colon. But getting there is a challenge.”

Dr. Abelson had no financial disclosures.

On Twitter @Alz_Gal

Recommended Reading

VIDEO: Anesthesia services during colonoscopy increase risk of near-term complications
MDedge Internal Medicine
Racial disparities in colon cancer survival mainly driven by tumor stage at presentation
MDedge Internal Medicine
Vedolizumab use linked to high rate of postoperative complications in IBD patients
MDedge Internal Medicine
Study eyes mortality among octogenarians after emergency Hartmann’s procedure
MDedge Internal Medicine
Anal cancer cases continue to rise, with disproportionately poorer outcomes for blacks
MDedge Internal Medicine
Optimal timing of CRC postop colonoscopy studied
MDedge Internal Medicine
VIDEO: Accelerated infliximab dosing halved colectomy rate in severe ulcerative colitis
MDedge Internal Medicine
Preoperative chemotherapy improves survival in patients with large anorectal GIST
MDedge Internal Medicine
Postop delirium linked to greater long-term cognitive decline
MDedge Internal Medicine
Study eyes anastomotic failure in stapled vs. hand-sewn techniques
MDedge Internal Medicine